:: ricerca cerca

iniziative news
da leggere segnaliamo
forum download

 Da leggere... 
Fuori tema 
Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)

Italian Journal of Pediatrics 2015, 41:97


Respiratory Syncytial Virus infections are one of the leading causes of severe respiratory diseases that require hospitalization and, in some cases, intensive care. Once resolved, there may be respiratory sequelae of varying severity. The lack of effective treatments for bronchiolitis and the lack of vaccines for RSV accentuate the role of prevention in decreasing the impact of this disease.

Prevention of bronchiolitis strongly relies on the adoption of environment and the hygienic behavior measures; an additional prophylactic effect may be offered, in selected cases, by Palivizumab, a humanized monoclonal antibody produced by recombinant DNA technology, able to prevent RSV infection by blocking viral replication.

After many years the Italian Society of Neonatology, on the basis of the most recent scientific knowledge, has decided to revise recommendations for the use of palivizumab in the prevention of RSV infection.


scarica il full text

Lina Bollani1, Eugenio Baraldi2, Gaetano Chirico3, Andrea Dotta4, Marcello Lanari5, Antonello Del Vecchio6, Paolo Manzoni7, Antonio Boldrini8, Piermichele Paolillo9, Sandra Di Fabio10, Luigi Orfeo11,
area download
 Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV) (188K)
stampa|elenco "da leggere"|forum >>

 :: home
 :: chi siamo

 :: direzione scientifica

 :: attivitą

 :: approfondimenti

 :: download

 :: link

home | mappa del sito | credits